Text Size:AAA

IFNA5 / IFNaG 抗体, ウサギポリクローナル抗体, Antigen Affinity Purified

データシートレビュープロトコル
製品の説明: Active  
発現宿主: Human Cells  
  • Slide 1
10342-H01H-50
10342-H01H-5
10342-H01H-100
50 µg 
5 µg 
100 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
51126-M02H-50
51126-M02H-100
50 µg 
100 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
51126-M08H-50
51126-M08H-100
50 µg 
100 µg 
Add to Cart
発現宿主: Yeast  
  • Slide 1
80205-R08Y-20
80205-R08Y-100
20 µg 
100 µg 
Add to Cart
製品の説明: Active  
発現宿主: Human Cells  
  • Slide 1
80205-R08H-50
80205-R08H-5
80205-R08H-100
50 µg 
5 µg 
100 µg 
Add to Cart

IFNA5/IFNaG AntibodyRelated Products

Related Products

Featured Reagent Products

IFNA5/IFNaG antibody 背景

Interferon, alpha 5 (IFNA5) belongs to the alpha/beta interferon family. IFNA5 is the only IFNA subtype detected in normal liver, while a mixture of subtypes is observed in the liver tissue of patients with chronic hepatitis C. Interferons are produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation.

人々 IFNA5/IFNaG antibody 参考文献
  • Lau JY, et al. (1993) Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 342(8881): 1208-9.
  • Kessler DS, et al. (1990) Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 4(10): 1753-65.
  • Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91(4): 1198-205.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"